Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BCMA CAR-NK in Relapsed/Refractory Multiple Myeloma
NCT05652530Phase 1Unknown
- Sponsor
- Shenzhen Puruijin Biological Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CAR NK in multiple myeloma (MM), sponsored by Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. Primary endpoints: Safety and Tolerability Assessment at Day 28 and Maximum Tolerated Dose. Status: unknown.
02
Drugs
BCMA-CAR NK
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05652530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652530.